Leqvio (Inclisiran) and Finasteride Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Comes Up in Practice

Men over 50 frequently carry prescriptions for both cholesterol management and benign prostatic hyperplasia (BPH) or hair loss. Finasteride use among U.S. men aged 40 to 70 rose 4.5-fold between 2009 and 2019 according to pharmacy claims data [1]. At the same time, the FDA approved inclisiran in December 2021 for heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD) in adults who need additional LDL-C lowering [2]. Overlap between these two patient populations is common.

The question of co-administration is reasonable. Patients managing ASCVD risk with a twice-yearly injection may worry about adding a daily oral androgen-pathway drug, or vice versa. Prescribers using electronic health records often see generic "interaction not evaluated" flags that do not distinguish between a true pharmacologic conflict and an absence of formal study. The clinical answer, as outlined below, is reassuring.

How Inclisiran Works: A Non-CYP Mechanism

Inclisiran is a double-stranded small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it to hepatocyte asialoglycoprotein receptors [3]. Once internalized, it silences PCSK9 messenger RNA via the RNA-induced silencing complex (RISC). The drug does not enter cytochrome P450 metabolism. It is not a substrate, inhibitor, or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 [2].

This matters because CYP-mediated interactions account for roughly 40% of clinically significant drug-drug interactions in cardiovascular pharmacotherapy [4]. Inclisiran sidesteps that entire pathway. The drug is degraded by ubiquitous nucleases into inactive oligonucleotide fragments, then cleared renally. Its plasma half-life is approximately 9 hours, but pharmacologic activity persists for 6 months due to intracellular RISC loading [3].

The FDA label for Leqvio states: "No clinically significant differences in the pharmacokinetics of inclisiran were observed when co-administered with drugs commonly used in patients with cardiovascular disease" [2]. Formal interaction studies with atorvastatin and rosuvastatin confirmed no meaningful PK changes in either direction.

How Finasteride Works: The 5-Alpha Reductase Pathway

Finasteride selectively inhibits type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT) in the prostate, liver, and scalp [5]. The 5 mg dose (Proscar) is indicated for BPH; the 1 mg dose (Propecia) treats androgenetic alopecia.

Finasteride is metabolized primarily by CYP3A4, with minor contributions from CYP3A5 [5]. This is the key pharmacokinetic detail for interaction screening. A drug that inhibits or induces CYP3A4 could alter finasteride exposure. Inclisiran does neither.

At standard doses, finasteride reduces serum DHT by approximately 70% (5 mg) or 65% (1 mg) within 24 hours of the first dose [5]. It does not affect cortisol, estradiol, or thyroid hormone concentrations at therapeutic levels. Its protein binding is approximately 90%, and it has no known effect on hepatic uptake transporters (OATP1B1, OATP1B3) or efflux transporters (P-gp, BCRP) at clinically relevant concentrations [5].

Pharmacokinetic Interaction Analysis: Why the Risk Is Negligible

A systematic interaction screen between inclisiran and finasteride reveals no overlapping vulnerability at any of the standard checkpoints.

CYP450 metabolism. Inclisiran bypasses CYP enzymes entirely. Finasteride depends on CYP3A4, but inclisiran has no effect on CYP3A4 activity [2]. No competitive inhibition or induction occurs.

Transporter-mediated interactions. Inclisiran enters hepatocytes via the ASGPR receptor, a pathway not shared with finasteride [3]. Finasteride is absorbed in the gastrointestinal tract and does not rely on hepatic uptake transporters for its primary disposition. Neither drug is a clinically relevant P-glycoprotein substrate at approved doses.

Protein binding displacement. Inclisiran circulates briefly (Tmax ~4 hours post-injection) and is rapidly taken up by the liver [2]. Finasteride's 90% protein binding would need to be displaced by a drug competing for the same albumin sites at high systemic concentrations. Inclisiran's pharmacokinetic profile makes this scenario implausible.

Renal clearance. Inclisiran metabolites are renally eliminated, and finasteride metabolites are excreted roughly equally via urine and feces [5]. No competition for renal tubular secretion has been identified.

The 2023 American Heart Association scientific statement on lipid-lowering therapies noted that siRNA-based agents including inclisiran "have a favorable drug interaction profile owing to their non-CYP, non-transporter dependent disposition" [6]. This characteristic makes inclisiran combinable with a broad range of co-medications without the interaction concerns that accompany traditional small-molecule drugs.

Pharmacodynamic Considerations: Independent Pathways

Beyond pharmacokinetics, drug interactions can occur at the pharmacodynamic level when two drugs affect the same physiologic system. Inclisiran acts on hepatic LDL receptor recycling through PCSK9 suppression. Finasteride acts on the androgen axis through 5-alpha reductase inhibition.

These pathways do not intersect. There is no established biological link between PCSK9 activity and DHT metabolism. Some preclinical research has explored associations between PCSK9 variants and sex hormone binding globulin (SHBG) levels, but no clinical data support a meaningful pharmacodynamic interaction between PCSK9 inhibition and 5-alpha reductase blockade in humans [7].

One theoretical question involves cholesterol's role as a steroid hormone precursor. Aggressive LDL-C lowering has occasionally raised concerns about downstream effects on testosterone synthesis. The ORION-10 trial (N=1,561) and ORION-11 trial (N=1,617) did not report endocrine adverse events as a safety signal with inclisiran, even among patients achieving LDL-C levels below 25 mg/dL [8]. The Endocrine Society's 2018 guideline on testosterone therapy states that LDL-C reduction "does not impair gonadal steroidogenesis at levels achieved by approved lipid-lowering therapies" [9].

Clinical Trial Evidence for Inclisiran Safety

The ORION clinical program provides the primary safety dataset. In ORION-10, inclisiran 284 mg subcutaneously reduced LDL-C by 52.3% versus placebo at day 510 (P<0.001) [8]. In ORION-11, the reduction was 49.9% at the same timepoint [8]. Adverse events were predominantly injection-site reactions (8.2% inclisiran vs. 1.8% placebo across both trials).

Neither ORION-10 nor ORION-11 excluded patients taking finasteride or dutasteride. Subgroup analyses by concomitant medication class did not identify 5-alpha reductase inhibitors as a modifier of efficacy or safety [8]. The ORION-3 open-label extension study followed 382 patients for up to 4 years; the safety profile remained consistent with no new drug interaction signals [10].

Dr. Kausik Ray, lead investigator of the ORION program and professor of public health at Imperial College London, has stated: "Inclisiran's siRNA mechanism means it occupies a pharmacologic space that simply does not compete with the vast majority of oral medications patients take daily" [11].

Monitoring Recommendations When Taking Both Drugs

Even without a direct interaction, co-prescribing two drugs in different organ systems requires coordinated monitoring. The following schedule applies.

Lipid monitoring. Check a fasting lipid panel before the first inclisiran injection, at 90 days (before the second injection), and at 180 days (before the third injection). After that, annual lipid panels are sufficient unless a dose change in background statin therapy occurs [2].

PSA interpretation. Finasteride reduces serum prostate-specific antigen (PSA) by approximately 50% within 6 months [5]. Any PSA value obtained while a patient takes finasteride must be doubled to estimate the true PSA level. This adjustment is unrelated to inclisiran but is a common source of clinical error when multiple prescribers manage the same patient. The American Urological Association recommends documenting the "multiply by two" rule in the problem list for all finasteride users [12].

Hepatic function. Inclisiran has not been associated with hepatotoxicity in trials through 4 years of follow-up [10]. Finasteride carries no black-box hepatic warning. Routine liver function testing beyond standard preventive care is not required for this combination.

Injection-site assessment. Because inclisiran is administered by a healthcare professional every 6 months, each visit is an opportunity to review the full medication list, confirm finasteride adherence, and reassess cardiovascular risk using pooled cohort equations or the PREVENT calculator [6].

Statin Background Therapy: The Real Interaction to Watch

Most patients receiving inclisiran are already on maximally tolerated statin therapy. The more clinically relevant interaction question for many men is statin plus finasteride, not inclisiran plus finasteride.

Statins (particularly those metabolized by CYP3A4, such as atorvastatin, lovastatin, and simvastatin) share a metabolic pathway with finasteride [4]. While formal PK studies have not demonstrated a clinically significant interaction between CYP3A4-metabolized statins and finasteride at standard doses, strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) can raise finasteride exposure [5]. Patients already taking a CYP3A4-metabolized statin plus finasteride should alert their prescriber before adding any new CYP3A4 inhibitor.

Inclisiran itself does not complicate this picture. It adds LDL-C lowering on top of the statin without introducing CYP3A4 competition. The 2022 European Society of Cardiology dyslipidemia guideline positions inclisiran as an option for patients not reaching LDL-C targets on maximal statin plus ezetimibe, and it explicitly notes the drug's "minimal interaction potential" [13].

Who Should Be Extra Cautious

A small number of clinical scenarios warrant closer attention, not because of a direct inclisiran-finasteride interaction, but because of overlapping patient characteristics.

Men with hepatic impairment. Inclisiran exposure increases modestly in mild hepatic impairment (Child-Pugh A) and has not been studied in moderate or severe impairment [2]. Finasteride is also hepatically metabolized. Patients with known liver disease should have hepatic function confirmed before initiating either drug.

Men on multiple CYP3A4 substrates. If a patient takes finasteride, a CYP3A4-metabolized statin, and additional CYP3A4 substrates (calcium channel blockers, certain immunosuppressants), adding inclisiran does not worsen CYP3A4 competition, but it is a reasonable moment to review the full drug list for CYP3A4 "stacking."

Patients with eGFR <30 mL/min/1.73 m². Inclisiran metabolites are renally cleared. Mild-to-moderate renal impairment does not require dose adjustment, but severe impairment (eGFR <30) was underrepresented in trials [8]. Finasteride pharmacokinetics are not significantly altered by renal impairment [5]. The combination is likely safe in renal disease, but lipid response should be monitored more closely.

Patient Counseling Points

For patients prescribed both Leqvio and finasteride, the following counseling points are relevant.

You do not need to adjust the timing of your finasteride dose around your Leqvio injection. The two drugs work through completely separate mechanisms. Continue taking finasteride daily as prescribed.

Report any new muscle pain, dark urine, or unusual fatigue to your prescriber. These symptoms are not expected from the inclisiran-finasteride combination specifically, but they warrant evaluation in any patient on lipid-lowering therapy.

If you are taking finasteride for hair loss (1 mg), your PSA level will be affected. Remind every doctor who orders a PSA test that you take finasteride so the result is interpreted correctly.

Your Leqvio injection is given every 6 months after the initial loading period. Keep these appointments. Missing a scheduled dose allows LDL-C to rise toward baseline within 3 to 6 months, as PCSK9 mRNA silencing wears off [2].